A Phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma

2003286 citationsJournal Article

Authors

Aminah Jatoi · Mayo Clinic

Neil M. Ellison

Patrick A. Burch · Mayo Clinic

Jeff A. Sloan · Mayo Clinic

Shaker R. Dakhil · Wichita Clinic

Paul J. Novotny

Winston Tan · WinnMed

Tom R. Fitch · Mayo Clinic in Arizona

Abstract

Green tea carries limited antineoplastic activity, as defined by a decline in PSA levels, among patients with androgen independent prostate carcinoma.

Topics & Keywords

Tea Polyphenols and Effects Cancer-related Molecular Pathways Advanced Breast Cancer Therapies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Cancer

Volume 97, Issue 6, pp. 1442-1446

DOI: 10.1002/cncr.11200

Field-Weighted Citation Impact: 12.19